Every material Form 8-K AEON Biopharma, Inc. has filed with the SEC since September 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 2, 2026, AEON Biopharma amended its two-year milestone warrants to reduce their exercise price from about $0.32 to $0.20 per share, with holders of at least 67% of the underlying shares agreeing. Certain holders have agreed to exercise at the lower price, and the company expects about $6.2 million in gross proceeds. The amendment applies to all outstanding warrants, which expire on November 16, 2026, after the FDA's September 30 feedback triggered accelerated expiration.
Exercise price cut from $0.3221 to $0.20 per common share, effective November 2, 2026
Company expects approximately $6.2 million in gross proceeds from warrant exercises
Amendment applies to all outstanding Two-Year Warrants; share count and expiration date unchanged
Warrants expire November 16, 2026; 71,517,020 common shares were outstanding as of October 30, 2026
AEON Biopharma made available a corporate presentation dated October 2026 on its investor relations website on October 23, 2026, and furnished it as Exhibit 99.1 under Item 7.01 of Form 8-K. The filing contains no financial results or guidance; the presentation outlines the company's plan for ABP-450 as a potential biosimilar alternative to BOTOX and states that the product has not been approved by the FDA for any therapeutic indication.
Presentation dated October 2026, made available on the company website October 23, 2026, and furnished as Exhibit 99.1
Presentation cites a $3.5 billion U.S. therapeutic botulinum toxin market in 2026, projected to reach $5.1 billion by 2031 per Clarivate
IND submission for the CMAP pharmacodynamic study planned for Q4 2026, with study initiation expected in Q1 2027
Presentation states ABP-450 has not been approved by the FDA for any therapeutic indication
AEON Biopharma received official minutes from its FDA Type 2b meeting on the development path for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with the company's two-stage pharmacodynamic study design and said previously completed Daewoong comparative studies may be submitted as supportive evidence, while the company will not start a standalone comparative efficacy study for now. The filing also says the Two-Year Milestone Warrants will expire on November 16, 2026, which affects warrant holders.
FDA agreed in principle with the two-stage CMAP pharmacodynamic study design; company expects to file an IND in Q4 2026 and start the study in Q1 2027
Previously completed Daewoong comparative studies may be considered as supportive evidence, subject to scientific bridging
No standalone comparative efficacy study planned at this time; company plans to return to the FDA in 2027
Two-Year Milestone Warrants will expire on November 16, 2026, unless exercised before that date
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AEON Biopharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →